DTC obesity med market heats up: Eli Lilly taps knownwell, Hims & Hers adds new weight loss meds to platform
Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as generics of Novo Nordisk's diabetes drug liraglutide through its weight loss platform.
Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...
Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...
Lilly, a sweet and social 1-year-old old terrier with a lot of positive qualities, is available for adoption at The Cat House ...
Genomic medicine company Sangamo Therapeutics said it entered a license agreement with Eli Lilly, under which Lilly received rights to employ Sangamo's proprietary capsid, STAC-BBB, for up to five ...
Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...
Lilly continues full-court press against breast cancer with women's March Madness event sponsorships
As the women’s NCAA March Madness tournament draws to a close, Eli Lilly is aiming for a slam dunk of its own. | As the women ...
Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...
Shares of Eli Lilly & Co. LLY shed 3.56% to $789.09 Thursday, on what proved to be an all-around dismal trading session for ...
Eli Lilly on Thursday expanded its direct-to-consumer online platform LillyDirect to include telehealth providers to diagnose ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback